BioSpace News Archive

InfuSystem Holdings, Inc. announced that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will participate in Lake Street Capital Markets’ 6th Annual Best Ideas Growth Conference on Wednesday, September 14, 2022.

Type I diabetes mellitus can be defined as a chronic illness characterized by the inability of the body to produce insulin due to an autoimmune disorder, in which the beta cells of the pancreas are destroyed by the body’s own immune system.

Novogene at the forefront of cutting-edge next-generation sequencing (NGS) services, has officially announced Falcon II, a superpowered robot scientist for autonomously intelligent NGS delivery.

SQZ Biotechnologies Company announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4.

Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in September.

DBV Technologies Announces Initiation of Phase 3 Study(VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years.

Medtronic plc, a global leader in healthcare technology, confirmed its participation in the following September 2022 investor conferences.

Exaktera LLC, (“Exaktera”), a Union Park Capital (“Union Park”) portfolio company, is pleased to announce its acquisition of Advanced Illumination Inc. (“Advanced Illumination”), a long-established design and manufacturer of specialty LED lighting assemblies and drivers for machine vision, industrial imaging, bio-medical and related imaging applications.

Elevar Therapeutics, Inc. announced top-line results from the Phase 3 study of its drug candidate rivoceranib combined with camrelizumab versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from KRYSTAL-1, a multicohort Phase 1/2 study, evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASG12C mutation.